Should You Buy Kestra Medical Technologies, Ltd. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Kestra Medical Technologies, Ltd. (KMTS) carries a solid Quality of Company rating of 5.8/10. Trading at $25.18, our multi-model framework evaluates whether the company's financial profile offers a favorable risk-reward setup.
The short answer: 0 of 0 CirclFi valuation models project upside for Kestra Medical Technologies, Ltd. (KMTS) at $25.18 — the models are evenly split, with a Quality Score of 5.8/10 and Value-Trap risk of 17/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Kestra Medical Technologies, Ltd. (KMTS) in 2026?
What Is the Bull Case vs the Bear Case for Kestra Medical Technologies, Ltd. (KMTS)?
| Bull case | Bear case |
|---|---|
| No active model projects meaningful upside for KMTS at $25.18. Bulls would have to argue that qualitative factors the models cannot measure will unlock value. | No active model flags significant downside for KMTS. The low Value Trap score paints a constructive picture. |
How Does KMTS Compare to Its Medical Instruments & Supplies Peers?
Valuation data pages: STXS · BNGO · XRAY · HBIO · POCI · CUPR · ALC · UTMD · STAA · ISRG · RMD
Which Other Stocks Score Like KMTS on Quality?
Closest companies to KMTS’s Quality of Company score of 5.8/10, across all industries.
- FTHM — Fathom Holdings Inc. (QOC 5.8) · analysis
- GLXY — Galaxy Digital (QOC 5.8) · analysis
- RGNX — REGENXBIO Inc. (QOC 5.8) · analysis
- JOBY — Joby Aviation, Inc. (QOC 5.8) · analysis
- OMDA — Omada Health, Inc. (QOC 5.8) · analysis
- GPMT — Granite Point Mortgage Trust Inc. (QOC 5.8) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
Which Medical Instruments & Supplies Screens Does KMTS Appear In?
So Is Kestra Medical Technologies, Ltd. (KMTS) Worth Buying in 2026?
Kestra Medical Technologies, Ltd. currently lacks sufficient model coverage for a definitive valuation conclusion. We recommend monitoring as additional SEC filing data becomes available.
These are quantitative model outputs, not investment recommendations. Kestra Medical Technologies, Ltd.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About KMTS Stock?
Should I buy KMTS stock right now?
Based on CirclFi's multi-model analysis, 0 of 0 models see upside for KMTS at $25.18. No active models currently project upside, suggesting the market price may already reflect or exceed fair value. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Kestra Medical Technologies, Ltd.?
Key risks include: limited model coverage (0/13 active), reducing analytical confidence; general market and sector-specific risks affecting Medical Instruments & Supplies companies. Always diversify and consult a financial advisor.
How does KMTS compare to its competitors?
Among Medical Instruments & Supplies peers, KMTS holds a Quality Score of 5.8/10. Comparable companies include STXS (QOC 6.1), BNGO (QOC 5.8), XRAY (QOC 6.1). The relative ranking helps investors identify whether KMTS offers better fundamental quality than alternatives in the same sector.
Is KMTS a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. KMTS's Quality Score of 5.8/10 suggests moderate fundamentals — not a clear long-term hold without further research into growth catalysts. Check our full data page for all 13 model estimates.
What price should I buy KMTS at?
CirclFi does not provide target buy prices or price alerts. However, our 0 active models produce fair value estimates ranging from — to —. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for KMTS.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad